238 related articles for article (PubMed ID: 27528054)
1. New Molecular Targets of Anticancer Therapy - Current Status and Perspectives.
Zajac M; Muszalska I; Jelinska A
Curr Med Chem; 2016; 23(37):4176-4220. PubMed ID: 27528054
[TBL] [Abstract][Full Text] [Related]
2. The synthesis review of the approved tyrosine kinase inhibitors for anticancer therapy in 2015-2020.
Liang X; Yang Q; Wu P; He C; Yin L; Xu F; Yin Z; Yue G; Zou Y; Li L; Song X; Lv C; Zhang W; Jing B
Bioorg Chem; 2021 Aug; 113():105011. PubMed ID: 34091289
[TBL] [Abstract][Full Text] [Related]
3. Tyrosine kinases as targets in cancer therapy - successes and failures.
Traxler P
Expert Opin Ther Targets; 2003 Apr; 7(2):215-34. PubMed ID: 12667099
[TBL] [Abstract][Full Text] [Related]
4. Molecular mechanisms of signal transduction: epidermal growth factor receptor family, vascular endothelial growth factor family, Kit, platelet-derived growth factor receptor, Ras.
Erman M
J BUON; 2007 Sep; 12 Suppl 1():S83-94. PubMed ID: 17935283
[TBL] [Abstract][Full Text] [Related]
5. Flavonoids as RTK inhibitors and potential anticancer agents.
Teillet F; Boumendjel A; Boutonnat J; Ronot X
Med Res Rev; 2008 Sep; 28(5):715-45. PubMed ID: 18080331
[TBL] [Abstract][Full Text] [Related]
6. Natural Sourced Inhibitors of EGFR, PDGFR, FGFR and VEGFRMediated Signaling Pathways as Potential Anticancer Agents.
Nandi S; Dey R; Samadder A; Saxena A; Saxena AK
Curr Med Chem; 2022; 29(2):212-234. PubMed ID: 33655823
[TBL] [Abstract][Full Text] [Related]
7. Small-molecule inhibitors of the receptor tyrosine kinases: promising tools for targeted cancer therapies.
Hojjat-Farsangi M
Int J Mol Sci; 2014 Aug; 15(8):13768-801. PubMed ID: 25110867
[TBL] [Abstract][Full Text] [Related]
8. VEGF signal system: the application of antiangiogenesis.
Liang X; Xu F; Li X; Ma C; Zhang Y; Xu W
Curr Med Chem; 2014 Mar; 21(7):894-910. PubMed ID: 24059233
[TBL] [Abstract][Full Text] [Related]
9. Kinase Inhibitor Indole Derivatives as Anticancer Agents: A Patent Review.
Rathi AK; Syed R; Singh V; Shin HS; Patel RV
Recent Pat Anticancer Drug Discov; 2017; 12(1):55-72. PubMed ID: 27697069
[TBL] [Abstract][Full Text] [Related]
10. New paradigms in anticancer therapy: targeting multiple signaling pathways with kinase inhibitors.
Faivre S; Djelloul S; Raymond E
Semin Oncol; 2006 Aug; 33(4):407-20. PubMed ID: 16890796
[TBL] [Abstract][Full Text] [Related]
11. Recent advances in the development of dual VEGFR and c-Met small molecule inhibitors as anticancer drugs.
Zhang J; Jiang X; Jiang Y; Guo M; Zhang S; Li J; He J; Liu J; Wang J; Ouyang L
Eur J Med Chem; 2016 Jan; 108():495-504. PubMed ID: 26717201
[TBL] [Abstract][Full Text] [Related]
12. Discovery of benzimidazole derivatives as novel multi-target EGFR, VEGFR-2 and PDGFR kinase inhibitors.
Li Y; Tan C; Gao C; Zhang C; Luan X; Chen X; Liu H; Chen Y; Jiang Y
Bioorg Med Chem; 2011 Aug; 19(15):4529-35. PubMed ID: 21724404
[TBL] [Abstract][Full Text] [Related]
13. Development of EGFR family small molecule inhibitors for anticancer intervention: an overview of approved drugs and clinical candidates.
Cheng W; Hu Y; Sheng R
Curr Med Chem; 2014; 21(38):4374-404. PubMed ID: 25245375
[TBL] [Abstract][Full Text] [Related]
14. Targeted therapies in bladder cancer--an update.
Black PC; Agarwal PK; Dinney CP
Urol Oncol; 2007; 25(5):433-8. PubMed ID: 17826665
[TBL] [Abstract][Full Text] [Related]
15. Cyclin-dependent protein kinase inhibitors including palbociclib as anticancer drugs.
Roskoski R
Pharmacol Res; 2016 May; 107():249-275. PubMed ID: 26995305
[TBL] [Abstract][Full Text] [Related]
16. Promoter methylation status of VEGF receptor genes: a possible epigenetic biomarker to anticipate the efficacy of intracellular-acting VEGF-targeted drugs in cancer cells.
Kim J; Hwang J; Jeong H; Song HJ; Shin J; Hur G; Park YW; Lee SH; Kim J
Epigenetics; 2012 Feb; 7(2):191-200. PubMed ID: 22395469
[TBL] [Abstract][Full Text] [Related]
17. The targeted therapy revolution in neuroendocrine tumors: in search of biomarkers for patient selection and response evaluation.
De Dosso S; Grande E; Barriuso J; Castellano D; Tabernero J; Capdevila J
Cancer Metastasis Rev; 2013 Dec; 32(3-4):465-77. PubMed ID: 23589060
[TBL] [Abstract][Full Text] [Related]
18. [Antineoplastic agents targeting tyrosine kinases].
Guren TK; Christoffersen T; Thoresen GH; Wisløff F; Dajani O; Tveit KM
Tidsskr Nor Laegeforen; 2005 Nov; 125(22):3115-9. PubMed ID: 16299568
[TBL] [Abstract][Full Text] [Related]
19. Anti-Angiogenics: Current Situation and Future Perspectives.
Zirlik K; Duyster J
Oncol Res Treat; 2018; 41(4):166-171. PubMed ID: 29562226
[TBL] [Abstract][Full Text] [Related]
20. Tyrphostins and other tyrosine kinase inhibitors.
Levitzki A; Mishani E
Annu Rev Biochem; 2006; 75():93-109. PubMed ID: 16756486
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
